{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:58:58Z","timestamp":1794859138253,"version":"4.9.1"},"reference-count":43,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T00:00:00Z","timestamp":1794787200000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Dasman Diabetes Institute and Kuwait Foundation for the Advancement of Sciences","id":[{"id":"https:\/\/ror.org\/03xr9q522","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,10,27]]},"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1136\/bmjopen-2026-125338","type":"journal-article","created":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:20:46Z","timestamp":1794853246000},"page":"e125338","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Tirzepatide Titration to Reduce side Effects (TiTRE) in individuals with obesity: a protocol for a randomised controlled trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct07574723","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07574723","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ebaa","family":"AlOzairi","sequence":"first","affiliation":[{"name":"Medical Division, Dasman Diabetes Institute, Kuwait City, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4333-7319","authenticated-orcid":false,"given":"Ameenah","family":"Alawadhi","sequence":"additional","affiliation":[{"name":"Clinical Care Research and Trials, Dasman Diabetes Institute, Kuwait City, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoub","family":"Alawadhi","sequence":"additional","affiliation":[{"name":"DAFNE Unit, Dasman Diabetes Institute, Kuwait City, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel","family":"Le Roux","sequence":"additional","affiliation":[{"name":"University College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,11,16]]},"reference":[{"key":"2026111610202437000_16.11.e125338.1","unstructured":"World Health Organization . World Health Organization: obesity and overweight 2025. 2025 Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"2026111610202437000_16.11.e125338.2","doi-asserted-by":"crossref","unstructured":"GBD. Risk Factors Collaborators . Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2021;2162\u2013203. doi:10.1016\/S0140-6736(24)00933-4","DOI":"10.1016\/S0140-6736(24)00933-4"},{"key":"2026111610202437000_16.11.e125338.3","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41366-025-01860-z","article-title":"Effects of weight control interventions on cardiovascular outcomes: an umbrella review of systematic reviews and meta-analyses","volume":"49","author":"Chen","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"2026111610202437000_16.11.e125338.4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802982"},{"key":"2026111610202437000_16.11.e125338.5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41366-025-01719-3","article-title":"Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map","volume":"49","author":"Lu","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"2026111610202437000_16.11.e125338.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03978-z"},{"key":"2026111610202437000_16.11.e125338.7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206038"},{"key":"2026111610202437000_16.11.e125338.8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"2026111610202437000_16.11.e125338.9","unstructured":"Rodriguez PJ , Goodwin Cartwright BM , Gratzl S , et al . Comparative effectiveness of semaglutide and tirzepatide for weight loss in adults with overweight and obesity in the us: a real-world evidence study. Primary Care Research [Preprint] 2023. doi:10.1101\/2023.11.21.23298775 Available: https:\/\/www.medrxiv.org\/content\/10.1101\/2023.11.21.23298775v1"},{"key":"2026111610202437000_16.11.e125338.10","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026111610202437000_16.11.e125338.11","unstructured":"Semaglutide and tirzepatide for obesity: effectiveness and value [Internet]. 2025. Available: https:\/\/icer.org\/wp-content\/uploads\/2025\/10\/ICER_Obesity_Evidence-Report_For-Publication_102925.pdf"},{"key":"2026111610202437000_16.11.e125338.12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/dom.15333","article-title":"Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials","volume":"26","author":"Patel","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026111610202437000_16.11.e125338.13","article-title":"Tirzepatide-induced gastrointestinal manifestations: a systematic review and meta-analysis","volume":"15","author":"Karrar","year":"2023","journal-title":"Cureus"},{"key":"2026111610202437000_16.11.e125338.14","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J Endocr Soc"},{"key":"2026111610202437000_16.11.e125338.15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2337\/db25-21-PUB","article-title":"21-PUB: a real-world adverse event profile of tirzepatide\u2014a pilot systematic review and meta-analysis of observational studies","volume":"74","author":"Deep Reddy Chitiki","year":"2025","journal-title":"Diabetes"},{"key":"2026111610202437000_16.11.e125338.16","unstructured":"Lilly\u2019s tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 | Eli Lilly and Company [Internet]. n.d. Available: https:\/\/lilly.gcs-web.com\/news-releases\/news-release-details\/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or"},{"key":"2026111610202437000_16.11.e125338.17","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","article-title":"Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026111610202437000_16.11.e125338.18","doi-asserted-by":"publisher","DOI":"10.2337\/db19-993-P"},{"key":"2026111610202437000_16.11.e125338.19","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1111\/dom.16554","article-title":"Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1","volume":"27","author":"Ard","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026111610202437000_16.11.e125338.20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026111610202437000_16.11.e125338.21","unstructured":"American College of Cardiology [Internet] . SURMOUNT-4: weight reversal post tirzepatide withdrawal. 2025. Available: https:\/\/www.acc.org\/latest-in-cardiology\/journal-scans\/2025\/12\/09\/16\/51\/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2fjournal-scans%2f2025%2f12%2f09%2f16%2f51%2fsurmount-4"},{"key":"2026111610202437000_16.11.e125338.22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jamainternmed.2025.6112","article-title":"Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity","volume":"186","author":"Horn","year":"2026","journal-title":"JAMA Intern Med"},{"key":"2026111610202437000_16.11.e125338.23","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1121387","article-title":"A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?","volume":"14","author":"Meng","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026111610202437000_16.11.e125338.24","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1111\/dom.16176","article-title":"Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials","volume":"27","author":"Rubino","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026111610202437000_16.11.e125338.25","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/S0140-6736(26)00656-2","article-title":"Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"407","author":"Horn","year":"2026","journal-title":"The Lancet"},{"key":"2026111610202437000_16.11.e125338.26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s40265-024-02084-7","article-title":"Dose individualisation of antimicrobials from a pharmacometric standpoint: the current landscape","volume":"84","author":"Preijers","year":"2024","journal-title":"Drugs"},{"key":"2026111610202437000_16.11.e125338.27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/cpt.3510","article-title":"Barriers and facilitators for bringing model-informed precision dosing to the patient\u2019s bedside: a systematic review","volume":"117","author":"Dibbets","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"2026111610202437000_16.11.e125338.28","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/jcph.70035","article-title":"A systematic evaluation of the dosing regimens for approved targeted therapies and immune checkpoint inhibitors in metastatic renal cell carcinoma from a Project OPTIMUS perspective","volume":"65","author":"Tan","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"2026111610202437000_16.11.e125338.29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1235947","article-title":"Pediatric oncology drug development and dosage optimization","volume":"13","author":"Cheung","year":"2023","journal-title":"Front Oncol"},{"key":"2026111610202437000_16.11.e125338.30","unstructured":"Lonza . Flexible-dose development strategies for today\u2019s clinical landscape\u2014executive summary. Pharmaceutical Technology [Internet]. 2025. Available: https:\/\/www.pharmtech.com\/view\/flexible-dose-development-strategies-for-today-s-clinical-landscape---executive-summary"},{"key":"2026111610202437000_16.11.e125338.31","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/psp4.12863","article-title":"Dose\/exposure-response modeling in dose titration trials: overcoming the titration paradox","volume":"11","author":"Kristensen","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026111610202437000_16.11.e125338.32","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-025-01055-4","article-title":"The drug titration paradox in the presence of intra-individual variation: can we estimate the true concentration-effect relationship?","volume":"27","author":"Goulooze","year":"2025","journal-title":"AAPS J"},{"key":"2026111610202437000_16.11.e125338.33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/cpt.2162","article-title":"The drug titration paradox: correlation of more drug with less effect in clinical data","volume":"110","author":"Schnider","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2026111610202437000_16.11.e125338.34","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2021.1831"},{"key":"2026111610202437000_16.11.e125338.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"2026111610202437000_16.11.e125338.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502081"},{"key":"2026111610202437000_16.11.e125338.37","unstructured":"Kuhre RE , Gabery S , Le Roux C , et al . Slow uptitration vs no uptitration of semaglutide results in similar body weight loss in diet-induced obese rats. In: Obesity facts.173."},{"key":"2026111610202437000_16.11.e125338.38","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2337\/dc25-0690","article-title":"Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: a randomized controlled open-label pilot study examining a 16-week flexible titration regimen versus label-recommended 8-week semaglutide titration regimen","volume":"48","author":"Eldor","year":"2025","journal-title":"Diabetes Care"},{"key":"2026111610202437000_16.11.e125338.39","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"The Lancet"},{"key":"2026111610202437000_16.11.e125338.40","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"2026111610202437000_16.11.e125338.41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14551"},{"key":"2026111610202437000_16.11.e125338.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504214"},{"key":"2026111610202437000_16.11.e125338.43","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-125338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:20:51Z","timestamp":1794853251000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-125338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11,16]]},"published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1136\/bmjopen-2026-125338"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-125338","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11]]}}}